Literature DB >> 21901586

[Fibromyalgia].

M Späth1.   

Abstract

Although chronic musculoskeletal pain represents the main symptom of fibromyalgia, those affected usually experience many and various accompanying symptoms of differing frequency and extent. While symptoms such as non-restful sleep, daytime fatigue, impaired memory and concentration, morning stiffness, as well as digestive and urination disorders help to establish the diagnosis, they represent a particular disease burden on patients, those around them and on the social system. Pathogenetic research is focussed increasingly on a central dysregulation in pain perception and pain processing, leading to the concept of "central sensitisation" as a final common pathway for fibromyalgia and similar syndromes. This supports the recommendations for prompt multimodal therapy based on pharmaco-, functional and behavioural therapy.

Entities:  

Mesh:

Year:  2011        PMID: 21901586     DOI: 10.1007/s00393-011-0783-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  173 in total

1.  Dolorimetry performed at 3 paired tender points highly predicts overall tenderness.

Authors:  F Petzke; A Khine; D Williams; K Groner; D J Clauw; R H Gracely
Journal:  J Rheumatol       Date:  2001-11       Impact factor: 4.666

2.  Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia.

Authors:  Samuel A McLean; David A Williams; Phyllis K Stein; Richard E Harris; Angela K Lyden; Gail Whalen; Karen M Park; Israel Liberzon; Ananda Sen; Richard H Gracely; James N Baraniuk; Daniel J Clauw
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

3.  Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia.

Authors:  Eric Guedj; Serge Cammilleri; Cecile Colavolpe; David Taieb; Catherine de Laforte; Jean Niboyet; Olivier Mundler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-13       Impact factor: 9.236

4.  Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Lesley M Arnold; R Michael Gendreau; Robert H Palmer; Judy F Gendreau; Yong Wang
Journal:  Arthritis Rheum       Date:  2010-09

5.  Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men.

Authors:  P N Prinz; K E Moe; E M Dulberg; L H Larsen; M V Vitiello; B Toivola; G R Merriam
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1995-07       Impact factor: 6.053

6.  A pilot study of body awareness programs in the treatment of fibromyalgia syndrome.

Authors:  S A Kendall; K Brolin-Magnusson; B Sören; B Gerdle; K G Henriksson
Journal:  Arthritis Care Res       Date:  2000-10

7.  The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Authors:  Philip J Mease; Daniel J Clauw; R Michael Gendreau; Srinivas G Rao; Jay Kranzler; Wei Chen; Robert H Palmer
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

Review 8.  Exercise for treating fibromyalgia syndrome.

Authors:  A J Busch; K A R Barber; T J Overend; P M J Peloso; C L Schachter
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro; Milagrosa Blanca; Angela Morcillo; Raquel Larios; Soledad Velasco; Carme Villarroya
Journal:  Arthritis Res Ther       Date:  2009-04-14       Impact factor: 5.156

Review 10.  Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome.

Authors:  Dina Dadabhoy; Leslie J Crofford; Michael Spaeth; I Jon Russell; Daniel J Clauw
Journal:  Arthritis Res Ther       Date:  2008-08-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.